Solid Biosciences (SLDB) Hisse Özeti

Solid Biosciences Inc. Amerika Birleşik Devletleri'nde nöromüsküler ve kardiyak hastalıklar için tedaviler geliştirmektedir. Daha fazla detay

SLDB temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 94.9% daha düşük bir oranda işlem görüyor

Gelirin yılda 59.6% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda US piyasasına kıyasla dalgalı hisse senedi fiyatı

SLDB Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Solid Biosciences Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Solid Biosciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$6.08
52 Haftanın En Yüksek Seviyesi	US$8.87
52 Haftanın En Düşük Seviyesi	US$2.68
Beta	2.47
1 Aylık Değişim	-29.55%
3 Aylık Değişim	2.70%
1 Yıllık Değişim	106.10%
3 Yıllık Değişim	-1.78%
5 Yıllık Değişim	-89.33%
Halka arzdan bu yana değişim	-98.21%

Son Haberler & Güncellemeler

Seeking Alpha • Mar 12

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Summary Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne Muscular Dystrophy [DMD]. The company demonstrated 60% mean microdystrophin expression at Day 90 in its phase 1/2 INSPIRE DUCHENNE trial, with safety confirmed in 40 patients. A $240 million private placement in March 2026 extends the cash runway, supporting key milestones through 2027. Upcoming catalysts include phase 3 IMPACT DUCHENNE first dosing in Q1 2026 and a potential FDA Accelerated Approval update by mid-2026. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Mar 12

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Analiz Makalesi • Oct 23

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Jul 09

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Apr 08

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Summary Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects. Despite risks, Solid's strong financial position and potential market disruption with SGT-003 make it a Buy, assuming continued safety and favorable Sarepta developments. Read the full article on Seeking Alpha

Seeking Alpha • Jan 21

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Summary Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025. SGT-501 is another gene therapy product candidate with an expected IND filing in the 1st half of 2025 for the treatment of patients with RYR2-mediated Catecholaminergic Polymorphic Ventricular Tachycardia. Read the full article on Seeking Alpha

Analiz Makalesi • Nov 16

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jul 26

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Solid...

Seeking Alpha • Apr 10

Buy Solid Biosciences: Unpacking Its Main Value Driver

Summary Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation. SLDB's valuation appears undervalued relative to its peers, which is why I ultimately lean bullish post-PIPE investment. Read the full article on Seeking Alpha

Seeking Alpha • Jan 17

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression. An IND filing to begin a phase 1 study using SGT-501 for the treatment of patients with catecholaminergic polymorphic ventricular tachycardia is expected by Q1 of 2025. Read the full article on Seeking Alpha

Seeking Alpha • Sep 30

Solid Biosciences to acquire gene therapy company AavantiBio

Life sciences company Solid Biosciences (NASDAQ:SLDB) will acquire the gene therapy company AavantiBio. The combined entity aims to advance a portfolio of neuromuscular and cardiac programs. The merger is subject to an approval by the shareholders of Solid. Post the transaction, the current CEO of AavantiBio, Bo Cumbo, will assume the role of president and CEO of Solid Biosciences. In support of the acquisition, SLDB has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $75M private placement. The private placement is expected to close concurrently with the closing of the merger in Q4. The combined entity is expected to have total cash and investments of ~$215M post the closing of the merger. SLDB shares were trading +17.47% pre-market. Source: Press Release

Analiz Makalesi • Apr 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...

Analiz Makalesi • Apr 28

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...

Analiz Makalesi • Mar 17

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Hissedar Getirileri

	SLDB	US Biotechs	US Pazar
7D	-21.2%	-4.9%	-1.0%
1Y	106.1%	28.1%	23.3%

Getiri vs. Endüstri: SLDB geçen yıl % 28.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: SLDB geçen yıl % 23.3 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is SLDB's price volatile compared to industry and market?
SLDB volatility
SLDB Average Weekly Movement	12.6%
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: SLDB hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: SLDB 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	121	Bo Cumbo	www.solidbio.com

Solid Biosciences Inc. Amerika Birleşik Devletleri'nde nöromüsküler ve kardiyak hastalıklar için tedaviler geliştirmektedir. Şirketin öncü ürün adayı, Duchenne musküler distrofisinin tedavisi için faz 1/2'de olan SGT-003'tür. Friedreich ataksisinin tedavisi için faz 1b klinik çalışmasında olan SGT-212'yi; katekolaminerjik polimorfik ventriküler taşikardi tedavisi için klinik öncesi aşamada olan SGT-501'i; TNNT2 aracılı dilate kardiyomiyopati tedavisi için klinik öncesi aşamada olan SGT-601'i geliştirmektedir; Klinik öncesi aşamada olan BAG3 aracılı dilate kardiyomiyopati tedavisi için SGT-401; keşif aşamasında olan RBM20 genindeki mutasyonlarla karakterize nadir kalıtsal hastalığın tedavisi için SGT-701; ve kardiyak ve diğer hastalıkların tedavisi için diğer ilaçlar.

Solid Biosciences Inc. Temel Bilgiler Özeti

Solid Biosciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SLDB temel i̇stati̇sti̇kler
Piyasa değeri	US$640.91m
Kazançlar(TTM)	-US$191.78m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-3.1x

F/K Oranı

SLDB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SLDB gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$191.78m
Kazançlar	-US$191.78m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.95
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

SLDB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/19 13:27
Gün Sonu Hisse Fiyatı	2026/05/19 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Solid Biosciences Inc. 22 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Timothy Chiang	BTIG
Kristen Kluska	Cantor Fitzgerald & Co.
Charles Duncan	Cantor Fitzgerald & Co.

Solid Biosciences (SLDB) Hisse Özeti

Ödüller

Risk Analizi

Solid Biosciences Inc. Rakipler

Candel Therapeutics

Lexeo Therapeutics

Immuneering

Lyell Immunopharma

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Solid Biosciences Doses First Participant in Phase 3 Impact Duchenne Clinical Trial Evaluating Sgt-003 in Duchenne Muscular Dystrophy

Solid Biosciences Inc., Annual General Meeting, Jun 10, 2026

New minor risk - Shareholder dilution

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Solid Biosciences Inc. Provides Interim Positive Clinical Update on Phase 1/2 Inspire Duchenne Trial

Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding from a group of investors

Recent updates

Solid Biosciences Doses First Participant in Phase 3 Impact Duchenne Clinical Trial Evaluating Sgt-003 in Duchenne Muscular Dystrophy

Solid Biosciences Inc., Annual General Meeting, Jun 10, 2026

New minor risk - Shareholder dilution

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Solid Biosciences Inc. Provides Interim Positive Clinical Update on Phase 1/2 Inspire Duchenne Trial

Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding from a group of investors

President notifies of intention to sell stock

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

President recently sold US$315k worth of stock

President exercised options and sold US$517k worth of stock

Solid Biosciences Inc. Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid Aav-Slb101

Solid Biosciences Inc Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Insufficient new directors

Solid Biosciences Inc. Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

President notifies of intention to sell stock

Solid Biosciences Inc. Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Inc. Receives Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Inc. Provides Update on Inspire Duchenne Clinical Trial Progress and Planned Regulatory Discussions

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

New minor risk - Share price stability

Solid Biosciences Inc. Receives FDA Fast Track Designation for SGT-501 First-In-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences Inc. Announces FDA IND and Health Canada CTA Approval for First-In-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from Russell Small Cap Comp Growth Index

Price target decreased by 7.2% to US$15.50

Solid Biosciences Inc. to Present At the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences Inc., Annual General Meeting, Jun 12, 2025

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

New major risk - Share price stability

New major risk - Shareholder dilution

Solid Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $199.987556 million.

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

New minor risk - Share price stability

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Solid Biosciences Inc. Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc. Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

President notifies of intention to sell stock

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Price target decreased by 9.0% to US$18.00

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Price target increased by 13% to US$19.78

Consensus revenue estimates increase by 123%

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Consensus EPS estimates upgraded to US$2.79 loss

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003

Consensus revenue estimates decrease by 50%, EPS upgraded

New minor risk - Share price stability

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Consensus revenue estimates decrease by 33%, EPS upgraded

New major risk - Revenue size

New minor risk - Market cap size

Solid Biosciences Inc. Announces Executive Changes

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Consensus forecasts updated